SCHEMBL12522017

SCHEMBL12522017

Cc1oc(-c2cccs2)nc1CN

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
ALDH1A1 P00352 10/20 0.50
HPGD P15428 5/20 0.50
HSD17B10 Q99714 5/20 0.48
MAPT P10636 6/20 0.47
LMNA P02545 1/20 0.47
PPARA Q07869 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
TP53 P04637 1/20 0.44
GFER P55789 1/20 0.44
PPARG P37231 2/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633793 0.86 KDM4E (0.54) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL1051606 0.84 KDM4E (0.53) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL4028821 0.84 KDM4E (0.53) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL13633782 0.83 HSD17B10 (0.53) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL7724076 0.82 KDM4E (0.51) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL5228001 0.82 ALDH1A1 (0.52) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL5103108 0.81 KDM4E (0.50) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL5800641 0.81 KDM4E (0.50) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL12447266 0.81 ALDH1A1 (0.53) KDM4EMEN1KMT2APOLBNPSR1
SCHEMBL5098263 0.80 KDM4E (0.63) KDM4EMEN1KMT2APOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835412-B2 Isoxazolidine derivatives CHIESI FARMACEUTICI S.P.A. (IT) 2014-09-16 US disclosed
US-20120238531-A1 ISOXAZOLIDINE DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2012-09-20 US disclosed
WO-2012123493-A2 ISOXAZOLIDINE DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2012-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238531-A1 ISOXAZOLIDINE DERIVATIVES IL5, TSLP, LTB4R2 KDM4E 4111/4885MEN1 4784/4885KMT2A 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.